Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib in EGFR or HER2 Exon 20–mutated NSCLC
CTR20191998Phase 2Terminated
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC), sponsored by Hanmi Pharmaceutical. Started Oct 2019; status: terminated.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20191998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191998.